CCM
DMIIR

Context Capital Management’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Context Capital Management’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60K Hold
750,000
– – ﹤0.01% 305
2026
Q1 		$60K Hold
750,000
– – ﹤0.01% 267
2025
Q4 		$105K Buy
+750,000
New +$107K ﹤0.01% 209

Other funds holding DMIIR

MCS
Mercuria Capital Strategies Houston, Texas $163M AUM 258.7% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Context Capital Management's DMIIR Position: Q2 2026 in Review

Context Capital Management held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q2 2026 at 750,000 shares worth $60K. The position accounts for ﹤0.01% of the portfolio, ranked #305.

Context Capital Management first reported a position in DMIIR in Q4 2025 and has held it in 3 quarters since. The position peaked at $105K in Q4 2025. 7 funds tracked by Wall St. Rank hold DMIIR as of Q2 2026.

  • Context Capital Management held 750,000 shares of Drugs Made In America Acquisition II Corp Right worth $60K as of Q2 2026.
  • Context Capital Management left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of Context Capital Management's portfolio in Q2 2026, its #305 holding.
  • Context Capital Management first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 3 quarters since.
  • Context Capital Management's Drugs Made In America Acquisition II Corp Right position peaked at $105K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q2 2026.

Based on Context Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.